Immunopathology and Infectious Diseases Melanoma-Associated Antigen Expression in Lymphangioleiomyomatosis Renders Tumor Cells Susceptible to Cytotoxic T Cells

From the Departments of Pathology, Microbiology and Immunology/Oncology Institute,* and Department of Surgery, Loyola University, Chicago, Illinois; Illinois Math and Science Academy, Aurora, Illinois; Department of Medicine, Loyola University, Chicago, Illinois; Department of Surgery, University of Chicago, Chicago, Illinois; Department of Dermatology, University of Cincinnati, Cincinnati, Ohio; and Department of Surgery,** Medical University of South Carolina, Charleston, South Carolina

[1]  V. Hearing,et al.  Physiological factors that regulate skin pigmentation , 2009, BioFactors.

[2]  E. Henske,et al.  Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells , 2009, Proceedings of the National Academy of Sciences.

[3]  H. Mal,et al.  Lung Transplantation for Lymphangioleiomyomatosis: The French Experience , 2008, Transplantation.

[4]  S. Toyooka,et al.  Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  J. Kirkwood,et al.  Next generation of immunotherapy for melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Magnussen,et al.  [Sporadic lymphangioleiomyomatosis. Clinical and lung functional characteristics of 32 female patients]. , 2008, Deutsche medizinische Wochenschrift.

[7]  E. Goncharova,et al.  Pulmonary lymphangioleiomyomatosis (LAM): Progress and current challenges , 2008, Journal of cellular biochemistry.

[8]  F. McCormack.  Lymphangioleiomyomatosis: a clinical update. , 2008, Chest.

[9]  G. Raposo,et al.  Premelanosome Amyloid-like Fibrils Are Composed of Only Golgi-processed Forms of Pmel17 That Have Been Proteolytically Processed in Endosomes* , 2008, Journal of Biological Chemistry.

[10]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[11]  R. Eisenberg,et al.  Cytologic findings of lymphangioleiomyomatosis in pleural effusion: a case report. , 2007, Acta cytologica.

[12]  P. Bohus,et al.  [Perivascular epithelioid cell tumor (PEComa) of the liver: a case report and review of the literature]. , 2007, Ceskoslovenska patologie.

[13]  P. Allavena,et al.  Role of tumor-associated macrophages in tumor progression and invasion , 2006, Cancer and Metastasis Reviews.

[14]  M. Nishimura,et al.  Therapeutic implications of autoimmune vitiligo T cells. , 2006, Autoimmunity reviews.

[15]  J. Wolchok,et al.  Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. , 2006, The Journal of clinical investigation.

[16]  H. Schmidt,et al.  Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  M. Nishimura,et al.  Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. , 2005, Cancer research.

[18]  J. Bonifacino.  Insights into the Biogenesis of Lysosome‐Related Organelles from the Study of the Hermansky‐Pudlak Syndrome , 2004, Annals of the New York Academy of Sciences.

[19]  M. Masri.  The mosaic of immunosuppressive drugs. , 2003, Molecular immunology.

[20]  H. Lyerly,et al.  Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes , 2002, Expert opinion on biological therapy.

[21]  L. Spitler.  Adjuvant therapy of melanoma. , 2002, Oncology.

[22]  N. Patronas,et al.  Meningiomas in lymphangioleiomyomatosis. , 2001, JAMA.

[23]  V. Engelhard,et al.  Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  R. Boissy,et al.  Keratinocytes play a role in regulating distribution patterns of recipient melanosomes in vitro. , 2001, The Journal of investigative dermatology.

[25]  E. Henske,et al.  The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. , 2001, American journal of respiratory and critical care medicine.

[26]  E. Henske,et al.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  V. Ferrans,et al.  Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. , 1999, American journal of respiratory cell and molecular biology.

[28]  F. Marincola,et al.  Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[29]  W. Westerhof,et al.  Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. , 1996, The American journal of pathology.

[30]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[31]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[32]  E. Medrano,et al.  Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. , 1991, The Journal of investigative dermatology.

[33]  N. Mazer,et al.  Kinetics of interleukin 2 mRNA and protein produced in the human T-cell line Jurkat and effect of cyclosporin A. , 1989, Biochemistry.